Evaluating Daily Weizmannia Bacillus Coagulans JBI-YZ6.3 Supplementation for Improving Constipation and Gut Health in Physically Active Adults Aged 18 to 50

What this Trial Is About

Researchers are evaluating the effects of a daily probiotic supplement called Weizmannia Bacillus coagulans JBI-YZ6.3 on gut health in healthy, physically active adults aged 18 to 50 years. The study aims to find out if this probiotic can improve constipation symptoms and overall gastrointestinal function compared to a placebo. It is a randomized, double-blind, placebo-controlled, crossover trial designed to provide controlled clinical evidence in this population. Participants will take part in two separate 4-week periods of supplementation one with the probiotic and one with a placebo. These periods are separated by a 4-week washout phase to avoid carryover effects. The probiotic or placebo will be taken once daily as capsules with water, with instructions to maintain consistent timing and to manage missed doses. Participants will be asked to keep their usual diet, exercise, and lifestyle habits during the study and avoid other probiotic or prebiotic supplements. Throughout the study, gastrointestinal symptoms will be assessed using validated questionnaires, focusing on constipation scores from the Gastrointestinal Symptom Rating Scale GSRS. Additional outcomes include other gastrointestinal symptoms and markers of gut comfort. Safety monitoring includes self-reported adverse events collected at each testing visit and weekly check-ins. Total participation lasts about 13 to 14 weeks, including screening and testing visits, which may be in person or virtual.

Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes